Cyclezyme advanced toward commercialization with a major European partner, strengthened its patent portfolio, and secured up to 24 months of funding. Financials show continued losses but a strong equity ratio and cash position.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.